The combined entity strengthens its expertise to help the pharmaceutical industry optimize its commercial performance in the face of increasing regulatory and commercial pressures on net revenues.
PHILADELPHIA, July 9, 2024 /PRNewswire/ — IntegriChain, which offers a comprehensive pharmaceutical technology, data, consulting and outsourcing platform for data-driven commercialization, today announced the acquisition of Federal Compliance Solutions (FCS), a leading pharmaceutical consulting and management services firm. This transaction creates the industry’s most comprehensive team of experts in government pricing and payer-provider contracting, areas that have simultaneously become more outsourced in the pharmaceutical industry and are the focus of significant regulatory and business changes. The combination builds on the technology, people, and process capabilities the two firms have developed to help the industry develop more cost-effective drug commercialization strategies, drive more profitable day-to-day business decisions, and improve net revenue controls around increasing price concessions for payers, providers, and channels.
“As drug pricing and reimbursement have become increasingly complicated, more and more pharmaceutical manufacturers have adopted outsourcing options where service providers perform pricing calculations and adjudicate rebates and chargebacks on their behalf,” he said. Josh HalpernCEO of IntegriChain. “This is a dynamic market with rapidly changing regulations, vertically integrating ecosystems, and increasingly diverse drug archetypes. IntegriChain and FCS together support over 200 manufacturer contracts and operations across pricing, gross-net, channel, and data with outsourcing solutions. We know that the success of the outsourcing model depends on delivering a differentiated experience to our customers and doing so proactively. That’s difficult to achieve without depth. We welcome FCS to our broad organization of over 200 experts across strategic consulting, advisory services, SaaS and BPaaS, and product and technology, all of whom proudly represent the leading team focused on improving the profitability of drug commercialization.”
“Now more than ever, pharmaceutical companies need a trusted partner, both to guide commercialization decisions and to drive technological efficiency,” he said. Rick MooreManaging Partner at FCS. “FCS has proven its trusted status through our focus on domain knowledge and quality. IntegriChain has established itself as a proven data and technology innovator, combining forces with others to create a leading Net Revenue Management consulting and outsourcing capability. We are excited to join the IntegriChain family and platform and look forward to our combined teams continuing to partner with pharmaceutical manufacturers of all sizes and types and driving innovation in contracts, pricing and gross-to-net ratio.”
The companies plan to jointly advance their portfolio of solutions and consulting services for today’s key business challenges, including increasingly complicated drug contracting, explosive 340B growth, the impact of the Inflation Reduction Act on pricing and reimbursement, and rapidly evolving drug distribution channels.
For the foreseeable future, there will be no changes to either IntegriChain or FCS’ advisory service delivery teams, systems, or processes. In 2025, the combined company will work to integrate advisory services and BPaaS offerings into the ICyte platform, driving innovation to deliver best-in-class offerings.
Under the terms of the agreement, IntegriChain acquired the equity of Federal Compliance Solutions . The entire management and professional team will join IntegriChain’s global workforce of nearly 750 professionals. This acquisition is IntegriChain’s seventh expansion. Fairmount Partners acted as exclusive financial advisor to FCS.
About Federal Compliance Solutions
Founded in 2017 by pharmaceutical industry experts, FCS is a leading life sciences consulting firm specializing in assisting pharmaceutical and biotechnology companies with strategies and solutions to optimize their government pricing, contracting, and gross-to-net revenue management. FCS’ experienced team of over 60 professionals has extensive experience across a wide range of government programs, SPTR, contracting, GTN, and FMV matters. FCS also supports pharmaceutical and biotechnology companies of all sizes with a broad range of daily operational processes and ongoing compliance requirements through its managed service offerings, including government pricing calculation and reporting, reimbursement and fee services, VA support, FMV and BFSF support, and GTN forecasting and accrual management.
About IntegriChain
IntegriChain helps pharmaceutical manufacturers bring their science to market, ensuring patients have affordable, timely, and sustainable access to therapy. IntegriChain offers the pharmaceutical industry’s only data-driven commercialization platform, from strategy to operational execution. The company’s unique approach to data, technology, consulting, and outsourcing helps connect the commercial, financial, and operational dimensions of drug access and profitability. Through the ICyte platform, IntegriChain enables pharmaceutical innovators to achieve better business outcomes by digitizing daily and recurring business activities and by integrating data and operations across procurement, pricing, channel and distribution, and gross-to-net. IntegriChain is backed by Nordic Capital, a leading private equity investor with a broad portfolio in healthcare and technology, and is headquartered in Philadelphia, PA, with offices in Ambler, PA, and Pune, India. For more information, please visit www.integrichain.com or follow on LinkedIn.
Contact
Jennifer Guinan, Sage Strategic Marketing, (email protected)
SOURCE IntegriChain
JOBs Apply News
For the Latest JOBs Apply News, Follow ©JOBs Apply News on Twitter and Linkedin Page.
